Floatz logo

Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer

Pancreatic Adenocarcinoma

Explore 185 assets in Pancreatic Adenocarcinoma →
Floatz Rating
C39/100
Confidence
Indicative
v0.2
Sponsor
Astellas Pharma Global Development, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05365581CT.gov
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
—Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Pancreatic Adenocarcinoma

AssetSponsorPhaseRating
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer (this asset)Astellas Pharma Global Development, Inc.P1C · 39
FluorouracilumJonsson Comprehensive Cancer CenterP4BBB
IrinotecanJonsson Comprehensive Cancer CenterP3BB
OxaliplatinJonsson Comprehensive Cancer CenterP4BB
DocetaxelBristol-Myers SquibbP2BB
OlaparibLantern Pharma Inc.P3BB
CapecitabineZhejiang UniversityP4BB
Irinotecan SucrosofateSWOG Cancer Research NetworkP3BB
Cis-Diamminedichloroplatinum IiJonsson Comprehensive Cancer CenterP2/3B

+42 more in the Pancreatic Adenocarcinoma cohort

Other indications for Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer

IndicationSponsorPhaseRating
Hepatocellular Carcinoma—P3BB · 65
Urothelial Carcinoma—P3BB · 64
Lung Cancer—P3B · 62

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer in Pancreatic Adenocarcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-vascular-endothelial-growth-factor-receptor-type-vegfr-2-extracellular-domain-human-monoclonal-imc-1121b-gamma-chain-disulphide-with-human-monoclonal-imc-1121b-kappa-chain-dimer-pancreatic-adenocarcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →